Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Lifeline Biotechnologies Inc

Company price
0.0003 USD -0.00 ( 25.00%)
Last update at 2026-11-17T20:08:00Z
VOLUME
1892000
Market Cap
1.30M

Momentum Score

…

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lifeline Biotechnologies Inc is an OTC Pink–listed company (LLBO.US); public filings and disclosures about its operations, products and financial condition are limited, so its core business is not well documented. Long-term growth would depend on successful development or commercialization of any biotechnological assets, regulatory approvals, strategic partnerships and reliable access to capital, which may benefit future expansion.
The most important investment risks are very limited public disclosure and low trading liquidity combined with high execution and financing risk tied to regulatory and clinical development outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
5.93
ROE
-
Net Debt
0.33M
ROCE
-105.61%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.06M -0.01M -0.00M -0.01M -
Net income -0.06M -0.01M -0.00M -0.01M -
Ebitda -0.06M -0.01M -0.00M -0.01M -
Depreciation and amortization - - - 0.23M 0.24M
Operating income -0.06M -0.01M -0.00M -0.01M -
Other operating expenses 0.06M 0.01M 0.00M 0.01M -
Total operating expenses 0.06M 0.01M 0.00M 0.01M -
Total other income expense net - - 0.00M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2018-12-31
Total assets - - - - 0.44M
Other current assets - - - - 0.00M
Total liab - - - - 0.39M
Total stockholder equity - - - - 0.06M
Other current liab - - - - 0.00M
Common stock - - - - 0.03M
Retained earnings - - - - -14.27M
Cash - - - - 0.00M
Total current liabilities - - - - 0.39M
Current deferred revenue - - - - 0.00M
Net debt - - - - 0.33M
Short term debt - - - - 0.33M
Short long term debt total - - - - 0.33M
Other stockholder equity - - - - -0.03M
Total current assets - - - - 0.18M
Net receivables - - - - 0.18M
Inventory - - - - 0.00M
Accounts payable - - - - 0.06M
Accumulated other comprehensive income - - - - 14.33M
Non currrent assets other - - - - 0.00M
Non current assets total - - - - 0.26M
Breakdown 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Total cashflows from investing activities - -0.08M - - -
Total cash from financing activities - -0.06M -0.05M 0.10M -0.05M
Net income - -0.04M 0.24M 0.01M 0.00M
Change in cash - 0.00M -0.00M 0.00M 0.00M
Begin period cash flow 0.00M 0.00M 0.00M 0.00M 0.00M
End period cash flow 0.00M 0.00M 0.00M 0.00M 0.00M
Total cash from operating activities - 0.14M 0.05M -0.10M 0.05M
Depreciation - - 0.00M 0.00M 0.00M
Change to account receivables - 0.15M -0.19M -0.11M 0.05M
Other cashflows from financing activities - -0.06M -0.05M 0.10M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - 0.18M -0.20M -0.11M 0.05M
Other non cash items - -0.18M 0.20M 0.11M -0.04M
Free cash flow - 0.14M 0.05M -0.10M 0.05M

Peer Comparison*

Sector: Financial Services Industry: Shell Companies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
LLBO
Lifeline Biotechnologies Inc
-0.00
25.00%
0.00 - - - -
CLUS
CLUS
-
-%
200.00 - - 0.09 0.92
SGDH
Sgd Holdings Ltd
-
-%
0.02 - - 59741.55 0.56
LION
Lionsgate Studios Holding Corp.
-
-%
13.74 - 23.31 1.13 1.35
QKIE
QKIE
-
-%
1.94 - - 470.20 -

Profile*

Lifeline Biotechnologies Inc

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.

1325 Airmotive Way, Reno, NV, United States, 89502

775-852-3222

Name Title Year Born
Mr. James D. Holmes CPA, MBA Chairman, Chief Exec. Officer and Treasurer NA
Dr. William H. Reeves Ph.D. Founder NA
Dr. Louis G. Keith M.D., Ph.D. VP, Medical Director, Sec. and Director NA
Mr. James D. Holmes CPA, MBA Treasurer & Chairman NA
Ms. Caren D. Currier President & CEO 1963
Dr. Louis G. Keith M.D., Ph.D. Vice President, Medical Director, Secretary and Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…